Studies of monogenic gastrointestinal diseases have revealed molecular pathways critical to gut homeostasis and enabled the development of targeted therapies.
CD55 Deficiency, Early-Onset PLE, and Thrombosis G enetic inquiry has contributed to our understanding of gastrointestinal diseases, associating at least 64 genes with early-onset or very-early-onset inflammatory bowel disease. 1 Deleterious gene variants affect the intestinal epithelial barrier, phagocytosis processes, immune regulation, and inflammation. Protein-losing enteropathy, or gastrointestinal protein wasting causing hypoproteinemia, edema, and pleural and pericardial effusions, has also been linked to monogenic disorders. 2 A loss-offunction variant in PLVAP (encoding plasmalemma vesicle associated protein) that disrupts endothelial fenestrated diaphragms and compromises barrier integrity is associated with severe proteinlosing enteropathy. 3 This condition can develop secondarily from systemic conditions that arrest lymph flow, such as congestive heart failure, or directly from gastrointestinal mucosal damage or impaired lymph drainage from primary intestinal lymphangiectasia (also known as Waldmann's disease). 2, 4 Although primary intestinal lymphangiectasia can be a component of multisystemic genetic syndromes, including the Hennekam syndrome (caused by biallelic loss-of-function variants in CCBE1 or FAT4), the mechanisms of nonsyndromic primary intestinal lymphangiectasia and protein-losing enteropathy remain largely unknown. 5, 6 Here, we define the molecular and clinical features of an autosomal recessive syndrome of early-onset protein-losing enteropathy characterized by primary intestinal lymphangiectasia, bowel inflammation, and thrombotic events.
Me thods

Study Participants
We enrolled 10 patients who were based in Turkey and 1 who was based in the Netherlands, along with their healthy parents and siblings when available. The 11 patients were from eight families, all of whom were of Moroccan, Syrian, or Turkish ancestry. Patients 3.1, 5.1, and 5.2 were assessed at the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna and were from Istanbul or Ankara, Turkey. The remaining patients were all assessed at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, in Bethesda, Maryland, and were from Turkey, Syria, or Morocco. The ages of the patients ranged from 3 to 23 years as of February 2017. Patients were initially identified on the basis of a diagnosis of persistent protein-losing enteropathy and were included in the study after the identification of biallelic loss-of-function variants in CD55. For details regarding individual patients, see the Supplemental Patient Clinical Histories section in the Supplementary Appendix, available with the full text of this article at NEJM.org. All the study participants provided written informed consent for approved protocols at their respective institutions, with consent for minors being provided by the parents.
Genetic and Functional Analysis
We performed whole-exome sequencing in the index patients and Sanger sequencing of CD55 in the other participants. Complement assays were performed before and after lentiviral CD55 reconstitution. Alexion Pharmaceuticals provided reagents. Details are provided in the Supplementary Appendix.
Statistical Analysis
We used the Mann-Whitney U test or Student's t-test to assess the significance between nonpaired samples and the Wilcoxon matched-pairs signedrank test or a two-tailed paired t-test for the paired samples. Two-tailed P values of less than 0.05 were considered to indicate statistical significance. Statistical comparisons were made with the use of GraphPad Prism software, version 7.0a.
R esult s
Clinical Phenotype
We investigated 11 patients and 2 deceased relatives with a history of protein-losing enteropathy that was characterized by early-onset gastrointestinal symptoms, edema, malnutrition, hypoalbuminemia, and hypogammaglobulinemia, from eight consanguineous families with unaffected parents (Table 1 and Fig. 1A , and Fig. S1 in the Supplementary Appendix). Hypoproteinemia was always present, with minor variations, and, together with edema and gastrointestinal symptoms (abdominal pain, vomiting, and diarrhea), was alleviated by albumin infusion (Fig. 1B) . Chronic malabsorption caused micronutrient deficiencies of iron, ferritin, calcium, magnesium, folate, and vitamins D and B 12 as well as anemia and growth retardation (Table 1) . These condi-T h e ne w e ngl a nd jou r na l o f m e dicine tions were improved by means of vitamin and micronutrient supplementation, a protein-rich diet with medium-chain triglycerides, albumin (administered as an intravenous infusion), and blood transfusions. Details are provided in Table S1,  Figures S1 and S2, and the Supplemental Patient  Clinical Histories section in the Supplementary  Appendix. Histopathological assessment of intestinalbiopsy samples or resections revealed extensive lymphangiectasia, verified by lymphatic endothelial markers, which, together with the patients' young age, suggested the diagnosis of primary intestinal lymphangiectasia (Table 1 and Fig. 1C) . 2, 4 Transmission electron microscopy of the duodenal-biopsy sample obtained from Patient 6.1 showed lymphatic dilatation, but, unlike in persons with PLVAP deficiency, we found normal capillary architecture. Surgical removal of the lymphangiectatic segments in Patients 2.1 (who had partial bowel obstruction), 5.1, and 5.2 ameliorated clinical symptoms and protein-losing enteropathy (although Patient 5.2 had a relapse), which raised the possibility of a causal relationship. Some patients had bowel inflammation (similar to that seen in persons with inflammatory bowel disease), exudates, and lymphocytic infiltrates without intestinal thromboses (Table 1 and Fig. 1D ). Radiologic examinations revealed bowel-wall edema, thickening, or both in Patients 1.1, 2.1, and 6.1. Thus, protein-losing enteropathy and micronutrient deficiencies are probably caused by primary intestinal lymphangiectasia exacerbated by bowel inflammation. Details are provided in Table S1 and Figures S3 and S4 Vitamin or micronutrient deficiency ‡ 11
Features of thrombotic disease § Thrombocytosis 2
Thrombosis 3
Endoscopic findings †
Mucosal ulcer 4
Lymphoid infiltrates in mucosa 6
Recurrent lung infection 5
Additional features
Hypothyroidism ¶ 3
Arthritis or arthralgia 2
Finger clubbing 5 * The CHAPLE syndrome comprises CD55 (decay-accelerating factor) deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy. † Two patients did not undergo endoscopic assessment because they did not have gastrointestinal symptoms. ‡ The micronutrients assessed included serum vitamin B 12 , vitamin D, folate, iron, ferritin, zinc, calcium, and magnesium. § Thrombi were located in the deep veins in the abdominal sites, including the mesenteric and hepatic veins, sometimes with extension to the inferior vena cava and heart, and leading to pulmonary embolism. ¶ Tests for antithyroglobulin and anti-thyroid peroxidase antibodies were negative. Three patients had severe thrombotic vascular occlusion (Table 1) . Thrombi developed in the inferior vena cava, right atrium, and pulmonary arteries of Patient 6.1, causing arteriovenous malformations (Fig. 1E) . Transmission electron microscopy of duodenal-biopsy samples revealed malformed erythrocytes binding abnormally to capillary walls and transmural migration. Patient 5.1 had multiple thromboses in the mesenteric and hepatic veins, heart, and cerebral veins that were associated with an intracranial hemorrhage. Thrombosis was unresolved, despite surgical removal of blood clots and anticoagulation. The Budd-Chiari syndrome developed in Patient 8.1, presumably owing to hepatic-vein thrombosis. Examination of extended family histories uncovered two additional patients, Patients 4.4 and 5.3, who had died before genotyping from thrombotic events associated with protein-losing enteropathy, lymphangiectasia, and malnutrition. Patient 6.1 died from pulmonary embolism during the course of the study. Hence, the natural history of the disease includes early death related to severe thrombotic events. Details are provided in Table S1 , Figures S1 and S6A through S6D, and the Supplemental Patient Clinical Histories section in the Supplementary Appendix.
Loss-of-Function Mutations in CD55
Whole-exome sequence analysis in Patients 1.1, 2.1, 3.1, and 5.1 revealed novel homozygous variants in the gene encoding the complement regulatory protein CD55 (encoding for decay-accelerating factor) ( Fig. 2A , and Table S3 and Figs. S1 and S7A in the Supplementary Appendix). 9 These variants segregated recessively with disease, and heterozygous persons were unaffected. These variants were not present in the Exome Aggregation Consortium (ExAC) database and were predicted by bioinformatic analysis to be deleterious (Table S4 in the Supplementary Appendix). Further screening of 640 patients with inflammatory bowel disease (some with early-onset or very-earlyonset disease) and a cohort of 239 samples obtained from Turkish persons revealed only 1 person heterozygous for a CD55 variant that was predicted to be only moderately deleterious (c.107delTGCCCGCGGCGC; Combined Annotation-Dependent Depletion [CADD] score, 13.23), which indicates that CD55 loss-of-function variants are rare. Screening of the ExAC database of 60,000 unrelated persons revealed 53 persons who were heterozygous for loss-of-function CD55 variants and 1 who was homozygous for a lossof-function CD55 variant, possibly from a cohort of persons with inflammatory bowel disease, although a lack of informed consent prevented us from identifying and contacting this person. CD55 had a probability of loss-of-function intolerance (pLI) score of 0.0, which indicates that heterozygous loss-of-function mutations are likely to be benign. 10 Screening of additional patients with early-onset protein-losing enteropathy revealed 6 patients who were homozygous for CD55 lossof-function variants in Families 4, 6, 7, and 8.
Patients 1.1 and 7.1 were homozygous for a dinucleotide deletion and a 4-nucleotide insertion at nucleotide positions 149 and 150. Patients 2.1, 3.1, 5.1, and 5.2 were homozygous for a singlenucleotide deletion in CD55 at position 109. Patient 8.1 was homozygous for a single-nucleotide insertion at position 367. All three variants resulted in a frameshift and were predicted to cause premature termination of CD55 messenger RNA (mRNA) translation. The variant common to Families 1 and 7 and the variant common to Families 2, 3, and 5 led to mRNA nonsense-mediated decay. In Family 4, a novel homozygous missense mutation in CD55 encodes a cysteine-to-serine substitution in the fourth short consensus repeat domain (c.800G→C, p.Cys267Ser); the wild-type Cys267 disulfide bond with Cys225 is presumably disrupted by the substituted serine at residue 267. 11 In Patient 6.1, a variant disrupting an exon 3 splice acceptor site probably caused alternative splicing. In all the patients, CD55 protein expression was lost, with only Patient 6.1 having minor residual expression (Fig. 2B, and Fig. S7D in the Supplementary Appendix). We observed that CD55 was normally expressed on capillary endothelial cells in the basal submucosa and lamina propria, the brush-border columnar epithelium, and infiltrating lymphocytes and was absent in tissues (Fig. 2C) . These variants have strong (in Patient 6.1) or very strong (in all our other patients) evidence of pathogenicity, according to the guidelines of the American College of Medical Genetics and Genomics. 12 Altogether, we identified five distinct homozygous, novel, loss-of-function CD55 variants in nine patients from Turkey, one from Syria, and one Fig. 2A) . Details are provided in Figures S1, S6E , and S7 in the Supplementary Appendix.
Complement Activation on CD55-Deficient Cells
CD55 is attached to the surface by a glycosylphosphatidylinositol moiety and inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage. 9 We therefore tested whether CD55 deficiency accelerated complement activation. 13, 14 After incubation with human serum, we observed increased C3 fragment deposition on patients' CD4+ T-cell blasts by staining for an epitope common to C3, C3b, and C3d, which was increased by means of stimulation of the classical pathway by coating the cells with mouse IgG1 (Fig. 3A and 3B) . We did not detect the C3b fragment (data not shown), which suggests rapid degradation, possibly by factor I and cofactor activity. 15 CD55 reconstitution reduced complement CD55 Deficiency, Early-Onset PLE, and Thrombosis deposition on T cells in patients (Fig. 3C) . Immunohistochemical analysis of duodenal-biopsy samples revealed in vivo terminal complement activation (membrane attack complex [C5b-9]) in submucosal arterioles (Fig. 3D) . Details are provided in Figure S7A and S7B in the Supplementary Appendix.
Excessive Production of Inflammatory Cytokines by CD55-Deficient T Cells
Complement proteins can provide costimulatory and differentiation signals to T cells by means of either CD46-mediated C3b sensing or anaphylatoxin receptors. [16] [17] [18] [19] [20] Studies in knockout mice have confirmed a role for Cd55 in adaptive immune regulation, with Cd55 −/− mice producing more interferon-γ and less interleukin-10 in autoimmune models. 21, 22 CD4+ T cells from patients produced an increased level of tumor necrosis factor (TNF), reduced the interleukin-10 level (with a normal interferon-γ level), and had normal proliferation after T-cell-receptor engagement. Dual inhibition of the anaphylatoxin receptors C3aR and C5aR1 decreased TNF overproduction to control levels, primarily owing to the inhibition of C5aR1. Anaphylatoxin inhibition did not increase the interleukin-10 level, which suggests that this defect in interleukin-10 production is independently regulated. 21 Inflammatory cytokines, including TNF, could instigate the severe thrombophilia in patients with CD55 deficiency by reducing thrombomodulin and augmenting tissue-factor expression on endothelial cells. 23 We found that TNF and interferon-γ induced procoagulatory decreases in thrombomodulin and increases in tissue factor. CD55 expression increased in human umbilical-vein endothelial cells after TNF treatment, which suggests that CD55 limits complement-mediated damage during inflammation.
CD55 can convey a costimulatory signal for T-cell activation and the production of interleukin-10, a cytokine that is inhibitory to intestinal inflammation. 24, 25 We found that patients' cells showed impaired proliferation and interleukin-10 production in response to an agonistic anti-CD55 antibody or recombinant CD97 together with T-cell-receptor stimulation. Details are provided in Figure S8 in the Supplementary Appendix.
In Vitro Inhibition of Complement by Eculizumab Formulation
Finally, we investigated whether clinically available complement inhibitors could prevent the enhanced activation in samples obtained from patients. We observed that C5a production, which was elevated on incubation with patients' cells, was abrogated by coincubation with an experimental formulation of eculizumab, a complement-inhibitory therapeutic agent that is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and the atypical hemolytic-uremic syndrome (Fig. 4) . T h e ne w e ngl a nd jou r na l o f m e dicine
Discussion
We define a genetic syndrome comprising CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (the CHAPLE syndrome). Protein-losing enteropathy is probably caused by primary intestinal lymphangiectasia, intestinal inflammation, and possibly thromboses (Fig. S9 in the Supplementary Appendix). 2, 4 Complement is a system of interacting proteins that provides host defense by destroying microbes and modulating immunity with soluble anaphylatoxins governed by multiple regulators, including CD55. 9 Genetic variants that increase complement activation cause PNH, the atypical hemolytic-uremic syndrome, C3 glomerulopathy, and age-related macular degeneration (Fig. S7A in the Supplementary Appendix). [26] [27] [28] PNH results from somatic mutations that disable the glycosylphosphatidylinositol anchor that tethers CD55 and CD59 to the cell surface, leading to complement-mediated hemolysis and thrombosis.
29-31 Heterozygous germline loss-of-function variants affecting C3, factor H, factor I, or CD46 trigger the atypical hemolytic-uremic syndrome by inducing complement-mediated damage to glomerular microvascular endothelial cells, hemolysis, and kidney failure. 32 These genetic defects also cause complement-mediated retinal damage and age-related macular degeneration. 33 Unlike PNH or the atypical hemolytic-uremic syndrome, isolated CD55 deficiency causes early-onset protein-losing enteropathy owing to primary intestinal lymphangiectasia and bowel inflammation. We found that CD55 is up-regulated by retinoic acid, which is highly concentrated in the gut from the diet (Fig.  S8G in the Supplementary Appendix). Persons with the CHAPLE syndrome and PNH are at increased risk for thrombosis, and thrombotic microangiopathy develops in patients with the atypical hemolytic-uremic syndrome. These findings indicate cross-regulation of the complement and coagulation cascades.
CD55 deficiency has been previously found in persons with sporadic gastrointestinal abnormalities who do not have Cromer blood group red-cell antigens (the Inab phenotype). [34] [35] [36] [37] The Inab phenotype can be transient (as has been observed in three cases) or persistent (as has been observed in nine cases) [34] [35] [36] [37] and is sometimes associated with gastrointestinal disease that has been variously diagnosed as Crohn's disease, capillary angioma, protein-losing enteropathy with intes- 
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P a t i e n t 1 . 1 P a t i e n t 2 . 1 C o n t r o l 1 P a t i e n t 4 . 1 P a t i e n t 4 . 2 P a t i e n t 4 . (Fig. S7G in the Supplementary Appendix), although no definitive correlation with disease was made. Also, exacerbated dextran sulfate sodium-induced colitis develops in Cd55-deficient mice, which is consistent with the intestinal disease seen in our patients, as does T-cell-mediated autoimmunity in autoimmune models, probably owing to immunoregulatory abnormalities that are similar to those seen in our patients. 21, 22, 38 Only one patient with the CHAPLE syndrome presented with autoimmunity in the form of polyarthritis, and none had inflammatory markers or elevated levels of cytokine in the blood.
The disease in our patients showed variable expressivity, which was potentially attributable to background genetics, diet, microbiome composition, or other influences. Conventional treatments were only transiently effective, although 
P<0.001
T h e ne w e ngl a nd jou r na l o f m e dicine more sustained benefit occurred after the resection of lymphangiectatic intestinal segments. Recurrent infections were responsive to intravenous immune globulin. Eculizumab, which suppressed C5a production on patients' cells, warrants further investigation as a potential treatment of the CHAPLE syndrome. 39 In line with this, work by Kurolap et al., published in this issue of the Journal, 40 shows that eculizumab therapy in a family with the CHAPLE syndrome resulted in attenuated protein-losing enteropathy and reduced bowel-movement frequency within 100 days after the initiation of therapy. Shown are the levels of C5a in supernatants of CD4+ T-cell cultures, color-coded according to patient, after 2 hours of incubation with 10% normal human plasma and 10 μg per milliliter of either isotype control or C5 inhibitory (m5G1.1) antibodies. Each triangle represents the average of at least three repeated measurements in a single donor or patient. The middle lines of the I bars indicate the sample mean, and the I bars ±1 SD. A two-tailed unpaired t-test with Welch's correction was performed for comparisons between the control group and the group of patients, and the two-tailed paired t-test was applied to comparisons of the same group with or without treatment.
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